Project Grant R41AI155038

This federal Project Grant award, provided by the National Institutes of Health (NIH) through the Research Infrastructure Programs (CFDA 93.351), aims to develop strategies for preventing or eliminating unwanted immune responses towards adeno-associated virus (AAV)-delivered anti-HIV broadly neutralizing antibodies. The $257,429 award to the University of Miami will fund a 2-year study involving 10 rhesus monkeys. The first aim will assess the ability of a combination drug treatment (rapamycin...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Cornell University a $435,412 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The goal of this 2-year project is to develop a biomaterial-driven, immunosuppressive platform that enables the re-administration of engineered adeno-associated virus (AAV) gene delivery vectors while maintaining their transduction efficiency....

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $284,331 to the University of Massachusetts Medical School (UMass Medical) to conduct research on the stability of gene therapy vectors based on adeno-associated virus (AAV) when challenged by natural viral infections. The objectives of this 2-year project are to: 1) Develop an in vitro model to track changes...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop complementary biotherapeutic delivery platforms to enable re-delivery of adeno-associated virus (AAV) gene therapies. The $1,095,274 award, with a performance period from August 1, 2024 to May 31, 2029, focuses on three key delivery platforms: 1) Targeted cell delivery of regulatory T cells to immunogenic cell death sites; 2)...

This Project Grant award of $704,635.00, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to develop optimized adeno-associated virus (AAV) vectors for gene therapy of hemophilia. The key focus is on engineering both the capsid and genome of AAV3 vectors to enhance their efficiency in transducing human hepatocytes, with the goal of achieving therapeutic efficacy at lower vector doses....

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $307,091 to Aleutian Therapeutics, Inc. to develop immune evasive strategies for allogeneic cell replacement therapies. The goal is to use gene editing of pluripotent stem cells to enable stem cell-derived cell therapies to be transplanted without the need for immunosuppressive drugs. The Phase I research will...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $986,387 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Children's Hospital of Philadelphia (CHOP) to identify cellular proteins associated with recombinant adeno-associated virus (rAAV) genomes. The project aims to employ a novel proteomics technology called IPOND-MS to identify cellular factors that interact with both wild-type AAV genomes and rAAV vector genomes during replication and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $561,538 to Abwiz Bio Inc. to develop neutralizing antibodies against Machupo virus, a New World arenavirus. The project aims to utilize an innovative, stabilized-trimer immunogen to discover and characterize antibodies targeting critical sites on the virus surface glycoprotein, in addition to the receptor-binding...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $1,640,169 to Synvivia, Inc. to validate a platform for identifying cyclic peptides that can dramatically increase the yield and quality of adeno-associated virus (AAV) vectors manufactured for gene therapy. The key objectives are to: 1) demonstrate that Synvivia's cyclic peptide discovery library contains molecules that...